- Home
- OPP vs IKT Comparison
OPP vs IKT Comparison
Compare OPP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | IKT |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 240.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPP | IKT |
|---|---|---|
| Price | $7.79 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 90.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.49 | $1.33 |
| 52 Week High | $8.77 | $2.37 |
Technical Indicators
Market Signals| Indicator | OPP | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 45.86 |
| Support Level | $7.49 | $1.43 |
| Resistance Level | $8.00 | $1.74 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 76.25 | 51.92 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.